417 related articles for article (PubMed ID: 14582454)
1. Acyl-coenzyme A:cholesterol acyltransferase inhibitors for controlling hypercholesterolemia and atherosclerosis.
Miyazaki A; Sakai M; Sakamoto Y; Horiuchi S
Curr Opin Investig Drugs; 2003 Sep; 4(9):1095-9. PubMed ID: 14582454
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of acyl-coenzyme a: cholesterol acyltransferase.
Miyazaki A; Kanome T; Watanabe T
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):463-9. PubMed ID: 16503866
[TBL] [Abstract][Full Text] [Related]
3. Potential role of acyl-coenzyme A:cholesterol transferase (ACAT) Inhibitors as hypolipidemic and antiatherosclerosis drugs.
Leon C; Hill JS; Wasan KM
Pharm Res; 2005 Oct; 22(10):1578-88. PubMed ID: 16180116
[TBL] [Abstract][Full Text] [Related]
4. Pyripyropene A, an acyl-coenzyme A:cholesterol acyltransferase 2-selective inhibitor, attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia.
Ohshiro T; Matsuda D; Sakai K; Degirolamo C; Yagyu H; Rudel LL; Omura S; Ishibashi S; Tomoda H
Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1108-15. PubMed ID: 21393580
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of acyl-CoA cholesterol acyltransferase by F12511 (Eflucimibe): could it be a new antiatherosclerotic therapeutic?
López-Farré AJ; Sacristán D; Zamorano-León JJ; San-Martín N; Macaya C
Cardiovasc Ther; 2008; 26(1):65-74. PubMed ID: 18466422
[TBL] [Abstract][Full Text] [Related]
6. [Development of new antiatherosclerotic agents--ACAT inhibitors and CETP inhibitors].
Miyazaki A; Horiuchi S
Nihon Rinsho; 1999 Dec; 57(12):2842-7. PubMed ID: 10638223
[TBL] [Abstract][Full Text] [Related]
7. Human acyl-CoA:cholesterol acyltransferase (ACAT) and its potential as a target for pharmaceutical intervention against atherosclerosis.
Chang C; Dong R; Miyazaki A; Sakashita N; Zhang Y; Liu J; Guo M; Li BL; Chang TY
Acta Biochim Biophys Sin (Shanghai); 2006 Mar; 38(3):151-6. PubMed ID: 16518538
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of SMP-797, a novel acyl-coenzyme a: cholesterol acyltransferase inhibitor with inducible effect on the expression of low-density lipoprotein receptor.
Ioriya K; Kino K; Horisawa S; Nishimura T; Muraoka M; Noguchi T; Ohashi N
J Cardiovasc Pharmacol; 2006 Feb; 47(2):322-9. PubMed ID: 16495773
[TBL] [Abstract][Full Text] [Related]
9. Acyl coenzyme A:cholesterol acyltransferase inhibition: potential atherosclerosis therapy or springboard for other discoveries?
Heinonen TM
Expert Opin Investig Drugs; 2002 Nov; 11(11):1519-27. PubMed ID: 12437499
[TBL] [Abstract][Full Text] [Related]
10. And then there were acyl coenzyme A:cholesterol acyl transferase inhibitors.
Meuwese MC; Franssen R; Stroes ES; Kastelein JJ
Curr Opin Lipidol; 2006 Aug; 17(4):426-30. PubMed ID: 16832167
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of acyl-CoA:cholesterol O-acyltransferase. synthesis and pharmacological activity of (+/-)-2-dodecyl-alpha-phenyl-N-(2,4,6-trimethoxyphenyl)-2H-tetrazole-5- acetamide and structurally related tetrazole amide derivatives.
O'Brien PM; Sliskovic DR; Picard JA; Lee HT; Purchase CF; Roth BD; White AD; Anderson M; Mueller SB; Bocan T; Bousley R; Hamelehle KL; Homan R; Lee P; Krause BR; Reindel JF; Stanfield RL; Turluck D
J Med Chem; 1996 Jun; 39(12):2354-66. PubMed ID: 8691430
[TBL] [Abstract][Full Text] [Related]
12. [MTP inhibitors and ACAT inhibitors. An update].
Ohashi K
Nihon Rinsho; 2002 May; 60(5):975-83. PubMed ID: 12030002
[TBL] [Abstract][Full Text] [Related]
13. Acyl-CoA:Cholesterol O-acyltransferase (ACAT) inhibitors. 2. 2-(1,3-Dioxan-2-yl)-4,5-diphenyl-1H-imidazoles as potent inhibitors of ACAT.
Astles PC; Ashton MJ; Bridge AW; Harris NV; Hart TW; Parrott DP; Porter B; Riddell D; Smith C; Williams RJ
J Med Chem; 1996 Mar; 39(7):1423-32. PubMed ID: 8691472
[TBL] [Abstract][Full Text] [Related]
14. Heterocyclic amides: inhibitors of acyl-CoA:cholesterol O-acyl transferase with hypocholesterolemic activity in several species and antiatherosclerotic activity in the rabbit.
White AD; Purchase CF; Picard JA; Anderson MK; Mueller SB; Bocan TM; Bousley RF; Hamelehle KL; Krause BR; Lee P; Stanfield RL; Reindel JF
J Med Chem; 1996 Sep; 39(20):3908-19. PubMed ID: 8831757
[TBL] [Abstract][Full Text] [Related]
15. A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels.
Ikenoya M; Yoshinaka Y; Kobayashi H; Kawamine K; Shibuya K; Sato F; Sawanobori K; Watanabe T; Miyazaki A
Atherosclerosis; 2007 Apr; 191(2):290-7. PubMed ID: 16820149
[TBL] [Abstract][Full Text] [Related]
16. Divergent pharmacologic activities of PD 132301-2 and CL 277,082, urea inhibitors of acyl-CoA:cholesterol acyltransferase.
Krause BR; Black A; Bousley R; Essenburg A; Cornicelli J; Holmes A; Homan R; Kieft K; Sekerke C; Shaw-Hes MK
J Pharmacol Exp Ther; 1993 Nov; 267(2):734-43. PubMed ID: 8246149
[TBL] [Abstract][Full Text] [Related]
17. Bavachin and isobavachalcone, acyl-coenzyme A: cholesterol acyltransferase inhibitors from Psoralea corylifolia.
Choi JH; Rho MC; Lee SW; Choi JN; Kim K; Song GY; Kim YK
Arch Pharm Res; 2008 Nov; 31(11):1419-23. PubMed ID: 19023538
[TBL] [Abstract][Full Text] [Related]
18. The hypolipidemic effect of a new ACAT inhibitor, VULM 1457, in diabetic-hypercholesterolaemic rats.
Adameová A; Kuzelová M; Faberová V; Svec P
Pharmazie; 2005 Sep; 60(9):714-5. PubMed ID: 16222877
[TBL] [Abstract][Full Text] [Related]
19. Importance of acyl-coenzyme A:cholesterol acyltransferase 1/2 dual inhibition for anti-atherosclerotic potency of pactimibe.
Kitayama K; Tanimoto T; Koga T; Terasaka N; Fujioka T; Inaba T
Eur J Pharmacol; 2006 Jul; 540(1-3):121-30. PubMed ID: 16730694
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of the ACAT inhibitor avasimibe (CI-1011).
Llaverías G; Laguna JC; Alegret M
Cardiovasc Drug Rev; 2003; 21(1):33-50. PubMed ID: 12595916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
